Edgar Filing: RUBICON MEDICAL CORP - Form SC TO-C

RUBICON MEDICAL CORP Form SC TO-C April 14, 2005

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE TO-C (Rule 13e-4)

Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934

RUBICON MEDICAL CORPORATION (Name of Subject Company (Issuer))

NEMO I ACQUISITION, INC. BOSTON SCIENTIFIC CORPORATION (Name of Filing Person (Issuer and Offeror)) _____

Common Stock, Par Value \$0.001 Per Share (Title of Class of Securities)

78112Q103

(CUSIP Number of Class of Securities)

Lawrence J. Knopf (508) 650-8000

Lawrence J. Knopf BOSTON SCIENTIFIC CORPORATION
One Boston Scientific Place
Natick, Massachusetts 01760-1537

NEMO I ACQUISITION, INC.
One Boston Scientific Place
Natick, Massachusetts 01760-1537 (508) 650-8000

(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing person)

> Copy to: Clare O'Brien, Esq. Shearman & Sterling LLP 599 Lexington Avenue New York, New York 10022-6069 (212) 848-4000

Calculation of Filing Fee

______ ______

Transaction valuation Amount of filing fee

N/A N/A

[_] Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

> Amount Previously Paid: N/A Form or Registration No.: N/A

Filing Party: N/A Date Filed: N/A

[X] Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

Edgar Filing: RUBICON MEDICAL CORP - Form SC TO-C

[_]	third party tender offer subject to Rule 14d-1.	
[X]	issuer tender offer subject to Rule 13e-4.	
[_]	going-private transaction subject to Rule 13e-3.	
[_]	amendment to Schedule 13D under Rule 13d-2.	
Check	the following box if the filing is a final amendment reporting the results	
of the tender offer. [_]		

EXHIBIT INDEX

Exhibit	
No.	Description
99.1	Joint Press Release issued by Boston Scientific Corporation and
	Rubicon Medical Corporation, dated April 14, 2005.